PT3615066T - Formulações de anticorpos anti-rankl humanos, e métodos para a sua utilização - Google Patents

Formulações de anticorpos anti-rankl humanos, e métodos para a sua utilização

Info

Publication number
PT3615066T
PT3615066T PT187246905T PT18724690T PT3615066T PT 3615066 T PT3615066 T PT 3615066T PT 187246905 T PT187246905 T PT 187246905T PT 18724690 T PT18724690 T PT 18724690T PT 3615066 T PT3615066 T PT 3615066T
Authority
PT
Portugal
Prior art keywords
formulations
methods
same
human anti
rankl antibodies
Prior art date
Application number
PT187246905T
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62165668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3615066(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT3615066T publication Critical patent/PT3615066T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT187246905T 2017-04-28 2018-04-27 Formulações de anticorpos anti-rankl humanos, e métodos para a sua utilização PT3615066T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492056P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
PT3615066T true PT3615066T (pt) 2024-03-08

Family

ID=62165668

Family Applications (2)

Application Number Title Priority Date Filing Date
PT187246905T PT3615066T (pt) 2017-04-28 2018-04-27 Formulações de anticorpos anti-rankl humanos, e métodos para a sua utilização
PT222067092T PT4190355T (pt) 2017-04-28 2018-04-27 Formulações de anticorpos anti-rankl humanos e métodos para a sua utilização

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT222067092T PT4190355T (pt) 2017-04-28 2018-04-27 Formulações de anticorpos anti-rankl humanos e métodos para a sua utilização

Country Status (37)

Country Link
US (3) US11192952B2 (pt)
EP (3) EP3615066B1 (pt)
JP (4) JP7190822B2 (pt)
KR (2) KR102681171B1 (pt)
CN (2) CN118987200A (pt)
AR (1) AR111497A1 (pt)
AU (2) AU2018260750B2 (pt)
BR (1) BR112019022188A2 (pt)
CA (1) CA3054165A1 (pt)
CL (3) CL2019003032A1 (pt)
CO (1) CO2019011463A2 (pt)
CR (2) CR20250034A (pt)
DK (2) DK4190355T3 (pt)
EA (1) EA201992570A1 (pt)
ES (2) ES2997833T3 (pt)
FI (2) FI3615066T3 (pt)
HR (2) HRP20240167T1 (pt)
HU (2) HUE065544T2 (pt)
IL (2) IL293127B2 (pt)
JO (2) JOP20190255B1 (pt)
LT (2) LT3615066T (pt)
MA (2) MA48462B1 (pt)
MX (1) MX2023013460A (pt)
MY (1) MY202479A (pt)
PE (2) PE20251534A1 (pt)
PH (1) PH12019502444A1 (pt)
PL (2) PL3615066T3 (pt)
PT (2) PT3615066T (pt)
RS (2) RS65299B1 (pt)
SG (1) SG11201909998TA (pt)
SI (2) SI4190355T1 (pt)
SM (2) SMT202400491T1 (pt)
TN (2) TN2019000297A1 (pt)
TW (2) TWI903512B (pt)
UY (2) UY40974A (pt)
WO (1) WO2018200918A1 (pt)
ZA (1) ZA202205141B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
SI4190355T1 (sl) 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
AU2019378544A1 (en) * 2018-11-16 2021-06-10 Samsung Bioepis Co., Ltd. Stable liquid composition comprising protein
CN109374779A (zh) * 2018-12-17 2019-02-22 杭州奕安济世生物药业有限公司 一种蔗糖含量的快速检测方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CA3155065A1 (en) * 2019-09-19 2021-03-25 Innovent Biologics (Suzhou) Co., Ltd. Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease
CN111704670B (zh) * 2020-08-18 2020-11-03 迈威(上海)生物科技股份有限公司 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
KR20230118573A (ko) * 2020-11-11 2023-08-11 에이치큐 한 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도
CN117062837A (zh) * 2021-05-12 2023-11-14 江苏恒瑞医药股份有限公司 特异性结合rankl和ngf的抗原结合分子及其医药用途
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
US20240343795A1 (en) 2021-08-12 2024-10-17 Amgen Inc. Antibody formulations
US20250297020A1 (en) * 2021-11-23 2025-09-25 Adalta Limited Rank-l binding molecules
WO2023179791A1 (en) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Treatment of musculoskeletal disorders
AU2023347288A1 (en) 2022-09-23 2025-03-13 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
CN120076828A (zh) * 2022-11-16 2025-05-30 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物
AU2024232412A1 (en) 2023-03-03 2025-09-25 Alvotech Hf Denosumab formulation
IL326572A (en) * 2023-08-17 2026-04-01 Sinomab Bioscience Ltd Antibodies targeting RANKL and sclerostin and their uses
WO2025116648A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
TW201019959A (en) 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
CN102946858B (zh) 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EA201391489A1 (ru) * 2011-04-07 2014-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
SI4190355T1 (sl) 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe

Also Published As

Publication number Publication date
KR102681171B1 (ko) 2024-07-05
PE20200343A1 (es) 2020-02-14
EP3615066B1 (en) 2023-12-27
JP7356525B2 (ja) 2023-10-04
IL293127B2 (en) 2024-06-01
EP4190355B1 (en) 2024-09-25
CR20250034A (es) 2025-03-06
KR20240110083A (ko) 2024-07-12
SG11201909998TA (en) 2019-11-28
CN110621342A (zh) 2019-12-27
PL4190355T3 (pl) 2025-02-10
JP7851438B2 (ja) 2026-04-24
TN2021000055A1 (en) 2022-10-03
JP2018188430A (ja) 2018-11-29
US20250326853A1 (en) 2025-10-23
MX2023013460A (es) 2023-12-15
TWI839331B (zh) 2024-04-21
WO2018200918A1 (en) 2018-11-01
IL268704A (en) 2019-10-31
CL2020002012A1 (es) 2020-10-16
EA201992570A1 (ru) 2020-03-20
US20200354463A1 (en) 2020-11-12
IL293127B1 (en) 2024-02-01
LT3615066T (lt) 2024-02-26
ZA202205141B (en) 2025-04-30
SI4190355T1 (sl) 2025-02-28
US20220143181A1 (en) 2022-05-12
PE20251534A1 (es) 2025-06-05
SMT202400491T1 (it) 2025-01-14
UY40974A (es) 2024-12-13
JP2025093923A (ja) 2025-06-24
HUE069382T2 (hu) 2025-03-28
DK3615066T3 (da) 2024-03-11
CA3054165A1 (en) 2018-11-01
TW202435914A (zh) 2024-09-16
JP2023166396A (ja) 2023-11-21
CN110621342B (zh) 2024-08-02
ES2973572T3 (es) 2024-06-20
HRP20241604T1 (hr) 2025-01-31
TN2019000297A1 (en) 2021-05-07
MA62173B1 (fr) 2025-01-31
EP4477667A3 (en) 2025-05-07
CN118987200A (zh) 2024-11-22
PH12019502444A1 (en) 2020-07-20
DK4190355T3 (da) 2024-12-09
MA48462A (fr) 2020-03-04
PT4190355T (pt) 2024-12-05
HRP20240167T1 (hr) 2024-04-26
KR20190140464A (ko) 2019-12-19
UY37707A (es) 2018-10-31
TW201841654A (zh) 2018-12-01
JOP20190255B1 (ar) 2024-12-22
AR111497A1 (es) 2019-07-17
SI3615066T1 (sl) 2024-04-30
DK3615066T5 (da) 2024-09-02
AU2025205470A1 (en) 2025-08-14
LT4190355T (lt) 2024-12-27
IL293127A (en) 2022-07-01
AU2018260750A1 (en) 2019-08-29
PL3615066T3 (pl) 2024-04-29
WO2018200918A8 (en) 2019-10-17
HUE065544T2 (hu) 2024-05-28
JP2022062059A (ja) 2022-04-19
CL2019003032A1 (es) 2020-02-21
SMT202400095T1 (it) 2024-05-14
JP7190822B2 (ja) 2022-12-16
FI4190355T3 (fi) 2024-12-07
AU2018260750B2 (en) 2025-04-17
ES2997833T3 (en) 2025-02-18
RS66284B1 (sr) 2025-01-31
CR20190538A (es) 2020-02-26
IL268704B (en) 2022-06-01
US11873343B2 (en) 2024-01-16
TWI903512B (zh) 2025-11-01
FI3615066T3 (fi) 2024-02-29
RS65299B1 (sr) 2024-04-30
EP4477667A2 (en) 2024-12-18
JOP20240115B1 (ar) 2025-10-01
EP4190355A1 (en) 2023-06-07
CO2019011463A2 (es) 2019-10-31
EP3615066A1 (en) 2020-03-04
BR112019022188A2 (pt) 2020-05-12
US11192952B2 (en) 2021-12-07
MA48462B1 (fr) 2024-05-31
MY202479A (en) 2024-04-30
CL2023002505A1 (es) 2024-03-08
JOP20190255A1 (ar) 2019-10-27

Similar Documents

Publication Publication Date Title
PT4190355T (pt) Formulações de anticorpos anti-rankl humanos e métodos para a sua utilização
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
IL278846A (en) Anti-CD3 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL270921A (en) Activatable anti-PDL1 antibodies and methods of using them
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL280321A (en) Antibodies against CXCR2 and their uses
IL278466B1 (en) Anti-DLL3 antibodies and their uses
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
IL283890A (en) Anti-periostin antibodies and their uses
IL292599A (en) tmem219 antibodies and medical uses thereof
HK40037554A (zh) 抗lrp5/6抗体和使用方法
HK40001499A (en) Anti-ryk antibodies and methods of using the same
HK1263275A1 (en) Anti-podocalyxin antibodies and methods of using the same